Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · September 01, 2021

Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma

Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Oncology
Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-Based Cohort
Clin Oncol (R Coll Radiol) 2021 Jul 02;[EPub Ahead of Print], D Ksienski, PT Truong, ES Wai, NS Croteau, A Chan, T Patterson, M Clarkson, S Hackett, S Irons, M Lesperance

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading